The earnings call highlighted progress in clinical trials and strategic plans for therapeutic platforms, but faced challenges with unmet primary endpoints and financial losses. The company is exploring strategic partnerships and remains optimistic about future developments.

Company Guidance

During the INmune Bio Second Quarter 2025 Earnings Call, the company provided guidance on multiple fronts. The call highlighted the Phase II MINDFuL trial results for XPro, which showed promise for Alzheimer's patients with high inflammation, representing 40% to 60% of the population. The trial confirmed the potential of XPro, with plans to pursue a strategic partnership to advance into Phase III, while also exploring the rare disease pathway for faster market access. The company anticipates an end-of-Phase II meeting with the FDA by year's end. Additionally, INmune Bio is preparing for a BLA submission for CORDStrom by mid-2026, targeting Recessive Dystrophic Epidermolysis Bullosa. The financials revealed a net loss of $24.5 million, with research and development expenses at $5.8 million, and cash reserves of approximately $33.4 million, expected to fund operations into Q3 2026.

XPro Phase II MINDFuL Trial Results

The trial confirmed that Alzheimer's patients with two or more biomarkers of inflammation are optimal candidates for XPro, aligning with the novel approach to Alzheimer's treatment. This subgroup represents 40% to 60% of Alzheimer's cases.

CORDStrom Program Progress

The company is focused on securing approval for CORDStrom for Recessive Dystrophic Epidermolysis Bullosa in the U.K. and U.S. by midyear 2026, with expectations that it will qualify for a Priority Review Voucher if approved in the U.S.

INKmune Phase I/II Program Completion

The program demonstrated safety and immunologic benefits, with plans to explore a trial focused on earlier-stage disease.

Financial Position

As of June 30, 2025, the company had cash and cash equivalents of approximately $33.4 million, sufficient to fund operations into Q3 of 2026.

Inmune Bio (INMB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

INMB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.33 / -	-0.6	―	―	―
Aug 07, 2025	2025 (Q2)	-0.38 / -1.05	-0.5	-110.00% (-0.55)
May 08, 2025	2025 (Q1)	-0.47 / -0.43	-0.61	29.51% (+0.18)	―
Mar 27, 2025	2024 (Q4)	-0.55 / -0.40	-0.47	14.89% (+0.07)	―
Oct 31, 2024	2024 (Q3)	-0.51 / -0.60	-0.48	-25.00% (-0.12)	―
Aug 01, 2024	2024 (Q2)	-0.63 / -0.50	-0.36	-38.89% (-0.14)	―
May 09, 2024	2024 (Q1)	-0.54 / -0.61	-0.36	-69.44% (-0.25)	―
Mar 28, 2024	2023 (Q4)	-0.43 / -0.47	-0.32	-46.87% (-0.15)	―
Nov 01, 2023	2023 (Q3)	-0.39 / -0.48	-0.43	-11.63% (-0.05)	―
Aug 07, 2023	2023 (Q2)	-0.40 / -0.36	-0.38	5.26% (+0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

INMB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.79	$2.56	-8.24%
May 08, 2025	$7.09	$6.97	-1.69%
Mar 27, 2025	$7.41	$7.52	+1.48%
Oct 31, 2024	$5.85	$6.04	+3.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Inmune Bio Inc (INMB) report earnings?

Inmune Bio Inc (INMB) is schdueled to report earning on Oct 29, 2025, TBA (Confirmed).

What is Inmune Bio Inc (INMB) earnings time?

Inmune Bio Inc (INMB) earnings time is at Oct 29, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is INMB EPS forecast?

INMB EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing